| Released | Contributor | Author | Title | Pages | Price |
| 4-Dec-2009 | New Constructs, LLC |
N/A
| INFI: Risk/Reward Rating: Full Report: Cash Truth Behind the Reported Earnings | 19 |
$10 |
| 3-Dec-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 3-Dec-2009 | Jefferson Research |
N/A
| Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of INFINITY PHARMACEUTICALS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. | 3 |
$20 |
| 3-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotechnology & Genetics Industry Market Research and Competitive Analysis 2010 | 569 |
$299 |
| 3-Dec-2009 | Plunkett Research, Ltd. | Jack W. Plunkett | Biotech & Genetics Industry Trends, Statistics & Analysis 2010 (Summary) | 71 |
$199 |
| 1-Dec-2009 | EconomicInvestor |
N/A
| "The Economy Matters" Report for INFI: the economy's impact on INFI's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 |
| 30-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for INFI | 13 |
$25 |
| 29-Nov-2009 | PriceTarget Research, Inc. |
N/A
| INFI has a current Overall Rating of D (Negative). | 7 |
$25 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 28-Nov-2009 | TheStreet.com Ratings |
N/A
| TheStreet.com Ratings Stock Report For: INFINITY PHARMACEUTICALS INC | 5 |
$25 |
0.22% Nasdaq 
Research Reports
